Over the last 4 years, insiders at AbCellera Biologics have traded over $394,042,033 worth of AbCellera Biologics stock and bought 6,630,906 units worth $88,015,834 . The most active insiders traders include Peter Thiel, Andrew Lo, and Holdings Ltd. Thermopylae. On average, AbCellera Biologics executives and independent directors trade stock every 23 days with the average trade being worth of $1,381,181. The most recent stock trade was executed by Holdings Ltd. Thermopylae on 29 August 2024, trading 283,516 units of ABCL stock currently worth $739,977.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics executives and other stock owners filed with the SEC include: